Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 7(55), p. 3613-3615, 2011

DOI: 10.1128/aac.01827-10

Links

Tools

Export citation

Search in Google Scholar

Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial ▿

Journal article published in 2011 by Lauriane Goldwirt, Joséphine Braun, Nathalie de Castro, Isabelle Charreau, Aurélie Barrail-Tran, Constance Delaugerre, François Raffi, Caroline Lascoux-Combe, Jean-Pierre Aboulker, Anne-Marie Taburet, Jean-Michel Molina
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT We compared tipranavir and darunavir concentrations measured at steady state in 20 human immunodeficiency virus (HIV)-infected patients enrolled in the EASIER-ANRS 138 clinical trial who switched from enfuvirtide to raltegravir while maintaining the same background regimen. The geometric mean ratios of the observed predose concentration ( C trough ), maximum concentration of drug observed in plasma ( C max ), and area under the plasma concentration-time curve (AUC) before (day 0) and after (week 24) the switch were 0.49, 0.76, and 0.67 and 0.82, 0.68, and 0.64 for tipranavir and darunavir, respectively. The virologic consequences of these drug interactions have yet to be determined.